A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR) - Regional Cancer Care Associates LLC

Clinical Trials

A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Breast Oncology
Locations
Bethesda
Sponsor
Sarah Cannon Research Institute
Protocol Number
BRE203
Cancer Diagnosis
To Learn More Call
201-510-0910